-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Deep Track Capital LP Invests $34.44 Million in Agenus Inc. (NASDAQ:AGEN)
Deep Track Capital LP Invests $34.44 Million in Agenus Inc. (NASDAQ:AGEN)
Deep Track Capital LP acquired a new position in shares of Agenus Inc. (NASDAQ:AGEN – Get Rating) in the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 13,998,491 shares of the biotechnology company's stock, valued at approximately $34,436,000. Agenus comprises approximately 2.2% of Deep Track Capital LP's investment portfolio, making the stock its 17th largest position. Deep Track Capital LP owned about 5.18% of Agenus at the end of the most recent reporting period.
Several other institutional investors have also modified their holdings of the company. U.S. Capital Wealth Advisors LLC acquired a new stake in Agenus during the 1st quarter worth $25,000. Bank of Nova Scotia purchased a new stake in shares of Agenus in the first quarter valued at about $31,000. Covestor Ltd purchased a new stake in shares of Agenus in the fourth quarter valued at about $32,000. Acadian Asset Management LLC purchased a new stake in shares of Agenus in the fourth quarter valued at about $32,000. Finally, Qube Research & Technologies Ltd purchased a new stake in shares of Agenus in the fourth quarter valued at about $40,000. 51.89% of the stock is owned by hedge funds and other institutional investors.
Get Agenus alerts:Wall Street Analysts Forecast Growth
Separately, TheStreet downgraded shares of Agenus from a "c-" rating to a "d" rating in a report on Friday, May 27th.
Agenus Stock Performance
Shares of AGEN stock opened at $2.69 on Friday. Agenus Inc. has a one year low of $1.25 and a one year high of $6.64. The company has a 50 day moving average price of $2.70 and a 200 day moving average price of $2.32. The firm has a market capitalization of $761.70 million, a price-to-earnings ratio of 26.90 and a beta of 1.17.Agenus (NASDAQ:AGEN – Get Rating) last posted its quarterly earnings data on Tuesday, August 9th. The biotechnology company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.06. Agenus had a net margin of 3.07% and a return on equity of 11.65%. During the same quarter in the prior year, the business posted ($0.37) EPS. As a group, equities analysts forecast that Agenus Inc. will post -0.7 EPS for the current fiscal year.
About Agenus
(Get Rating)
Agenus Inc, a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Further Reading
- Get a free copy of the StockNews.com research report on Agenus (AGEN)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Want to see what other hedge funds are holding AGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agenus Inc. (NASDAQ:AGEN – Get Rating).
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.
Deep Track Capital LP acquired a new position in shares of Agenus Inc. (NASDAQ:AGEN – Get Rating) in the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 13,998,491 shares of the biotechnology company's stock, valued at approximately $34,436,000. Agenus comprises approximately 2.2% of Deep Track Capital LP's investment portfolio, making the stock its 17th largest position. Deep Track Capital LP owned about 5.18% of Agenus at the end of the most recent reporting period.
根据深轨资本有限公司与美国证券交易委员会的最新披露,该公司在第一季度收购了Agenus Inc.(美国证券交易委员会代码:AGEN-GET评级)的新股票头寸。该基金收购了这家生物技术公司13,998,491股股票,价值约34,436,000美元。Agenus约占Deep Track Capital LP投资组合的2.2%,使其成为其第17大头寸。截至最近一次报告期末,Deep Track Capital LP拥有Agenus约5.18%的股份。
Several other institutional investors have also modified their holdings of the company. U.S. Capital Wealth Advisors LLC acquired a new stake in Agenus during the 1st quarter worth $25,000. Bank of Nova Scotia purchased a new stake in shares of Agenus in the first quarter valued at about $31,000. Covestor Ltd purchased a new stake in shares of Agenus in the fourth quarter valued at about $32,000. Acadian Asset Management LLC purchased a new stake in shares of Agenus in the fourth quarter valued at about $32,000. Finally, Qube Research & Technologies Ltd purchased a new stake in shares of Agenus in the fourth quarter valued at about $40,000. 51.89% of the stock is owned by hedge funds and other institutional investors.
其他几家机构投资者也调整了对该公司的持股。美国资本财富顾问公司(U.S.Capital Wealth Advisors LLC)在第一季度收购了Agenus价值2.5万美元的新股份。丰业银行在第一季度购买了价值约3.1万美元的Agenus新股。Covestor Ltd在第四季度购买了Agenus的新股份,价值约3.2万美元。Acadian Asset Management LLC在第四季度购买了Agenus的新股份,价值约3.2万美元。最后,Qube Research&Technologies Ltd在第四季度购买了Agenus的新股份,价值约为4万美元。51.89%的股票由对冲基金和其他机构投资者持有。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
Separately, TheStreet downgraded shares of Agenus from a "c-" rating to a "d" rating in a report on Friday, May 27th.
另外,华尔街在5月27日星期五的一份报告中将Agenus的股票评级从C-下调至D。
Agenus Stock Performance
Agenus股票表现
Agenus (NASDAQ:AGEN – Get Rating) last posted its quarterly earnings data on Tuesday, August 9th. The biotechnology company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.06. Agenus had a net margin of 3.07% and a return on equity of 11.65%. During the same quarter in the prior year, the business posted ($0.37) EPS. As a group, equities analysts forecast that Agenus Inc. will post -0.7 EPS for the current fiscal year.
纳斯达克(Agen-Get Rating)最近一次公布季度收益数据是在8月9日,星期二。这家生物技术公司公布了该季度每股收益(0.17美元),比分析师普遍预期的(0.23美元)高出0.06美元。Agenus的净利润率为3.07%,股本回报率为11.65%。在前一年的同一季度,该业务公布了每股收益(0.37美元)。作为一个整体,股票分析师预计Agenus Inc.本财年每股收益将为0.7%。
About Agenus
关于Agenus
(Get Rating)
(获取评级)
Agenus Inc, a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Agenus公司是一家临床阶段的免疫肿瘤学公司,在美国和国际上发现和开发免疫肿瘤学产品。该公司提供Retrocell Display,这是一个抗体表达平台,用于识别完全人类和人源化的单抗;以及展示技术。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Agenus (AGEN)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- 免费获取StockNews.com关于阿吉恩(Agen)的研究报告
- MarketBeat:回顾一周9/5-9/9
- 为网络安全股创纪录的季度做准备
- 汽车市场正在缓慢复苏,这些股票可能表现优异
- DocuSign是否即将发生重大逆转?
- 石油和天然气股票:投资可再生能源的安全途径
Want to see what other hedge funds are holding AGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agenus Inc. (NASDAQ:AGEN – Get Rating).
想看看其他对冲基金持有Agen的是什么吗?请访问HoldingsChannel.com获取Agenus Inc.(纳斯达克代码:AGEN-GET Rating)的最新13F备案和内幕交易信息。
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Agenus Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Agenus和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧